–Poster Highlights the Potential of Oral Small Molecule IFNAR Agonists Program to Improve Tolerability by Engaging the IFNα Pathway in a Liver-Focused Approach–
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB) is a biotechnology company developing innovative antiviral therapies for serious viral diseases. Today announced new data from its virology portfolio in two presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting®
taking place in Boston from November 10-14, 2023.William Delaney, Ph.D., said: “These data underscore our continued commitment to advancing innovative programs that have the potential to transform the treatment paradigm for patients affected by severe viral diseases and highlight our preclinical IFNAR agonists in the lead optimization phase. Project prospects.” Chief Scientific Officer, Assembly Bio. “In addition, Phase 2 data on vebicorvir in combination with Nrtl and Arbutus Biopharma’s AB-729 provide further insights that may inform future studies by the HBV and liver disease scientific community.”
Titled “in vitro and live “Analysis of Orally Bioavailable Small Molecules Inhibiting Hepatitis B Virus by Mimicking Interferon Alpha” highlights preclinical data describing hepatitis B virus (HBV) and hepatitis C virus (HCV) inhibition in vitro Activation of interferon (IFN) signaling by novel small-molecule interferon-alpha (IFNα) receptor (IFNAR) agonists. The IFNAR agonists described in this poster closely mimic the biological activity of IFNα in vitro By stimulating cytokine secretion and inducing interferon-stimulated genes (ISG) after treatment of human cells. Furthermore, oral administration in preclinical species resulted in ISG induction in liver and peripheral blood mononuclear cells (PBMC).
Additionally, an oral presentation was scheduled titled “Treatment of patients with virologically suppressed hepatitis B and antigen-negative chronic hepatitis B using the combination of velbicovir, nucleos